Despite ArQule's (ARQL -2.4%) disappointing top-line results from its Phase 2 trial of...

|By:, SA News Editor

Despite ArQule's (ARQL -2.4%) disappointing top-line results from its Phase 2 trial of tivantinib in patients with refractory or relapsed colorectal cancer, Burrill Institutional Research thinks its use in treating hepatocellular carcinoma (HCC) could still drive shares higher. In patients with HCC, Tivantinib demonstrated statistically significant results versus a placebo in reducing tumor progression, and the firm thinks the treatment could reach global peak sales of $278M.